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BACKGROUND: Gene expression profiling has distinguished sporadic breast tumour classes with genetic and clinical differences. Less is
known about the molecular classification of familial breast tumours, which are generally considered to be less heterogeneous. Here,
we describe molecular signatures that define BRCA1 subclasses depending on the expression of the gene encoding for oestrogen
receptor, ESR1.
METHODS: For this purpose, we have used the Oncochip v2, a cancer-related cDNA microarray to analyze 14 BRCA1-associated
breast tumours.
RESULTS: Signatures were found to be molecularly associated with different biological processes and transcriptional regulatory
programs. The signature of ESR1-positive tumours was mainly linked to cell proliferation and regulated by ER, whereas the signature
of ESR1-negative tumours was mainly linked to the immune response and possibly regulated by transcription factors of the REL/NFkB
family. These signatures were then verified in an independent series of familial and sporadic breast tumours, which revealed a possible
prognostic value for each subclass. Over-expression of immune response genes seems to be a common feature of ER-negative
sporadic and familial breast cancer and may be associated with good prognosis. Interestingly, the ESR1-negative tumours were
substratified into two groups presenting slight differences in the magnitude of the expression of immune response transcripts and
REL/NFkB transcription factors, which could be dependent on the type of BRCA1 germline mutation.
CONCLUSION: This study reveals the molecular complexity of BRCA1 breast tumours, which are found to display similarities to
sporadic tumours, and suggests possible prognostic implications.
British Journal of Cancer (2009) 101, 1469–1480. doi:10.1038/sj.bjc.6605275 www.bjcancer.com
& 2009 Cancer Research UK
Keywords: gene expression profiling; BRCA1-associated tumours; prognosis
                                                               
Breast cancer is a complex disease, encompassed by different
clinically and molecularly stratified entities. In 2000, Perou
and colleagues demonstrated that tumour phenotypic diversity
correlates with differences in global gene expression patterns,
which in turn reflect aspects of the biological behaviour of the
tumours (Perou et al, 2000). This study and subsequent ones
(Sorlie et al, 2001; van‘t Veer et al, 2002; Bertucci et al, 2006)
provide detailed analysis of correlations with histopathological and
clinical characteristics.
The level of expression of the oestrogen receptor (ER) is a key
feature that divides breast tumours into two main clusters.
ER-positive tumours include the luminal A and luminal B
subclasses showing different prognosis (Perou et al, 2000).
Tumours with very low or no detectable expression of ER can be
classified into HER2/ErbB2-positive, normal breast-like and basal-
like (Perou et al, 2000; Sorlie et al, 2001). The first subclass is
characterised by over-expression of ERBB2 and other genes at the
17q22 amplicon. Normal breast-like tumours show high hetero-
geneity, with expression of genes related to the adipose tissue and
other nonepithelial cells (Sorlie et al, 2001). Finally, the basal-like
subclass is known to be negative for HER2/ErbB2, ER and the
progesterone receptor (PR), and characterised by the expression of
genes from the basal epithelium with high frequency of TP53
mutations (Sorlie et al, 2001; Foulkes et al, 2004; Bertucci et al,
2006; Turner and Reis-Filho, 2006; Yehiely et al, 2006; Adelaide
et al, 2007; Jumppanen et al, 2007). Basal-like tumours account for
up to 15% of all breast cancers and the clinical handling of this
subclass is a major challenge, once they do not respond to
conventional targeted therapies.
Similar features in familial breast cancer are less clearly
understood, partially due to the fact that very few studies
have been published regarding expression profiling of the
corresponding breast tumours. This lack of information probably Received 27 February 2009; revised 17 July 2009; accepted 27 July 2009
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slies in the difficulty to collect frozen tumours from hereditary
breast cancer cases genetically characterised. This is also reflected
in the small size of the series that have been published so far. In
2001, Hedenfalk et al (2001) examined a small series of tumours
from patients with germline mutations in BRCA1 or BRCA2
genes and differentiated two groups within BRCA1. They suggested
that the DNA repair and apoptosis pathways were altered in the
BRCA1 tumours and that, although most of these were ER
negative, ER status alone was not sufficient to discriminate
both classes. In a subsequent study, Hedenfalk et al (2003)
proposed novel classes for the familial non-BRCA1/BRCA2
breast tumours and a different expression profile to those of
the BRCA1- and BRCA2-associated tumours reported earlier
(Hedenfalk et al, 2003).
More recently, it has been suggested that most tumours arising
in BRCA1 mutation carriers display a basal-like phenotype, with
the percentages reported ranging from 44 to almost 100% (Diaz
et al, 2007; Melchor and Benitez, 2008). It is not yet known whether
there are differences in the molecular or clinical characteristics
within BRCA1 or between BRCA1 and sporadic basal-like tumours.
Two recent expression profiling studies have revealed further
stratification of the sporadic ER-negative breast tumours (Kreike
et al, 2007; Teschendorff et al, 2007). Kreike et al (2007) reported
that basal-like tumours can be divided into five different
subclasses and linked the presence of lymphocytic infiltrate and
central fibrotic zones to lower risk of metastasis. In addition,
Teschendorff et al (2007) defined four ER-negative subgroups
whose clinical outcomes differ according to the expression of genes
of the immune response.
Here, we used expression profiling to classify the BRCA1 breast
tumours and applied an integrative approach to examine biological
dependencies and differences. Tumours were initially segregated
according to the expression of ESR1 gene or the expression of basal
markers. Detailed examination of the profiles of apparently
uniform classes revealed molecular differences within both the
ESR1-positive and ESR1-negative tumours. These subclasses were
corroborated in an independent series of familial and sporadic
breast tumours, which revealed possible prognostic value. We
suggest that BRCA1 breast tumours show a high degree of
molecular complexity and define the wiring diagram of signalling
pathways involved in their tumorigenesis.
MATERIALS AND METHODS
Tumoral tissues
Fourteen frozen tumours from patients harbouring germline
mutations in BRCA1 were used (Supplementary Table S4). Samples
proceeded from CNIO (Madrid), Istituto Tumori (Milan), Hospital
Clı ´nico San Carlos (Madrid) and ICO (Barcelona). Patient selection
and mutational analysis are described elsewhere (Diez et al, 2003;
Manoukian et al, 2007). A tissue microarray containing an
independent series of 15 BRCA1 tumours previously classified as
basal or luminal-like phenotype (Palacios et al, 2005) was used to
analyse the CD133 (Prominin 1) and MMP7 (Matrix Metallopro-
teinase 7) proteins. Immunohistochemical staining was performed
by the Labelled Streptavidin-Biotin method (Dako, Glostrup,
Denmark) with a heat-induced antigen retrieval step. Immuno-
fluorescence was performed with a fluorescence-labelled secondary
antibody (Alexa 488 for MMP7 and Alexa 555 for CD133).
Evaluation of tumour samples
Frozen tumour samples were included in a polyvinyl matrix
(OCT). A slice of each sample was stained with hematoxilin-eosin
and examined by a pathologist to determine the amount of tumoral
cells; those with a tumour content 470% were used for subsequent
RNA extraction.
RNA extraction, cDNA labelling and hybridisation
Total RNA extraction was performed (TRIZOL, Invitrogen,
Carlsbad, CA, USA) and mRNA was amplified from 5mg of total
RNA (SuperScript II, Invitrogen and Ambion, Austin, TX, USA). A
new cDNA was synthesised from the amplified mRNA and labelled
with Cy5. The same process was carried out with the Universal
Human Reference RNA (Stratagene, La Jolla, CA, USA), which was
labelled with Cy3. Hybridisation was performed onto the CNIO
human OncoChip V2 following standard conditions (Tracey et al,
2002).
Quantitative RT–PCR
DNA-free total RNA was obtained from a set of 10 breast cancer
cell lines including the BRCA1-mutant cell line MDA-MB-436
(previously hybridised onto the Oncochip V2). One microgram of
RNA was reverse transcribed using MMLV retrotranscriptase
(Invitrogen) and random hexamers. Quantitative PCR assays were
set up in triplicate for the BRCA1 target gene and two control genes
(BACT and MRPL19). Assays were designed using the Roche
Applied Science Universal Probe Library web site for BRCA1
(probe 11) and MRPL19 (probe 42). BACT primers and probe are
described elsewhere. The relative expression of BRCA1 was
determined using the free access qBase software (Hellemans
et al, 2007), which is based on a modification of the classic delta–
delta Ct method that allows for PCR efficiency correction and
multiple control gene normalisation.
Microarray data analyses
Two channel ratios (Cy5/Cy3) for each spot were generated and
quantified using GenePix Pro 5.1 (Axon Instruments, Inc., Union
City, CA, USA). Data were normalised with the print-tip loess
method (Yang et al, 2002) and log2-transformed values, and
filtered using the PREPROCESSOR tool (Montaner et al, 2006).
Differentially expressed genes were declared after applying a two-
tail t-test with the P-values adjusted for the false discovery rate
(FDR) using the Tibshirani and Efron approach (Tibshirani and
Efron, 2002). Representation of Gene Ontology (GO) terms was
examined using the Onto-Express tool (Khatri et al, 2007), with the
reference including all genes in the array that passed quality filters
and with P-values calculated based on the hypergeometric
distribution and corrected using the FDR approach. Unsupervised
clustering was performed in the R programming language (82)
using the Euclidean distance and Ward’s minimum variance
method, except in the analysis of basal markers, which was
performed with the correlation and average-linkage clustering
method. A bootstrapping resampling approach in the R library
pvclust (Suzuki and Shimodaira, 2006) was applied to assess
clustering robustness. Data from van‘t Veer et al (2002) were log2-
transformed and cross-mapped with our gene lists using Entrez
gene identifiers manually curated for all possible probes matching
each gene. Histopathological and clinical information was down-
loaded from the publication site.
Transcription factor and interactome analyses
Examination of predicted transcription factor binding sites was
performed using the oPOSSUM tool (Ho Sui et al, 2005), with
promoters defined as  2 kilobases (kb) to the start of transcrip-
tion, and using JASPAR annotations with a matrix match threshold
of 80%. Fisher’s exact test was used to examine the results for over-
representation and using the Bonferroni correction taking into
account the number of motifs analysed (n¼111). Experimentally
identified binding sites for ER and E2F1 were taken from the
original publications or relevant databases (Carroll et al, 2006; Jin
et al, 2006). We assigned ER cis-regulators to the closest known
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sgene locus (50 end) in the May 2004 version of the human genome
in the UCSC Genome Browser. The human interactome network
was built by combining three previously published data sets, which
consist mainly of experimentally verified interactions. The data set
based on the Human Protein Reference Database (Gandhi et al,
2006) contains compiled and filtered binary protein interactions
from most currently available databases. High-confidence yeast
two-hybrid interactions from Pujana et al (2007) and Stelzl et al
(2005) were then incorporated, and orthology-based predictions
and homodimers were excluded to avoid bias. Proteins with no
assigned Entrez GeneID were also excluded from the analyses.
Shortest distances were calculated using only the giant network
component and the geodesic formulation given by Freeman (Stelzl
et al, 2005) using the R programming language (82). Differences
between distributions of shortest paths were assessed with the
Mann–Whitney U-test and GO term representations evaluated
with the Onto-Express tool (Khatri et al, 2007), taking as a
reference the protein set of the giant network component.
RESULTS
ESR1-status or the basal-like phenotype as major
classifiers
Unsupervised clustering of the 5570 genes that remained after data
filtering (see Materials and Methods) stratified the whole series of
14 BRCA1 tumours into two main branches (Figure 1A). This
clustering was clearly mediated by ESR1 expression: one cluster
(five samples, right branch) over-expressed this gene whereas the
rest (nine samples, left branch) mostly showed very modest or
undetectable ESR1 expression.
Examination of the ‘intrinsic gene list’ (Perou et al, 2000; Hu
et al, 2006), and an exhaustive review of the literature (Perou et al,
2000; Sorlie et al, 2003) identified a set of 55 established
markers present in our platform that were subsequently used for
classification (Figure 1B). Two main groups were identified, one
over-expressing markers typically found in sporadic luminal
tumours such as GATA3, TFF1 and SCUBE2 (right panel), and
the other negative for ESR1, ERBB2 and the PR gene (PGR) (triple
negative) and over-expressing genes from the basal layer such as
CDH3, CRYAB and KRT5-17 (left panel). This clustering showed
consistent results with the previous classification with the
exception of sample #33 that shared characteristics of both basal
and luminal classes. As the classification with the 55 markers was
in agreement with the immunohistochemical data for this sample
(ER and PGR positive, Supplementary Table S4) we decided to
maintain it within the ESR1-positive class.
BRCA1 tumour subclasses and signatures
Using the set of 5570 genes that passed filtering criteria (see
Materials and Methods for data quality evaluation), we examined
differential expression within the BRCA1 classes relative to the
common reference. Applying a FDR of 1 out of 1000, 212 genes
were differentially expressed within the class of ESR1-positive
tumours (hereafter, gene-set #1) and 670 genes differentially
expressed within the class of ESR1-negative tumours (gene-set #2)
(Supplementary Tables S1 and S2, respectively).
Biological differences between the two gene-sets were revealed
by analysing GO term annotations (see Materials and Methods).
Taking into account the number of genes annotated for each term
and the 5570 genes, the top-ranked biological processes in gene-set
#1 were transcription, DNA-dependent and cell cycle, whereas the
top-ranked in gene-set #2 were the immune response and cell
cycle. Consistent with the association with cell proliferation (Butt
et al, 2007), response to oestrogen stimulus was found to be over-
represented in gene-set #1 but not in gene-set #2. In addition,
analysis of functional genomic data of the ER-positive cell line
MCF7 (Carroll et al, 2006) identified a higher than expected
number of genes in gene-set #1 to be transcriptionally regulated by
the ER signalling pathway. Thirty-three (15%) genes in this set
showed significant transcriptional changes on ER signalling and
chromatin immunoprecipitation assays identified a cis-ER-binding
site in a further 60 (28%). Finally, the gene-set #2 also contained
several tumour suppressors (EPHA3 and EPHB2) and proto-
oncogenes (AKT1, AURKA, ETV6, MITF and PIK3CA), which
expands on the observed enrichment of the immune response and
suggests that this gene-set has a critical role in breast tumorigen-
esis. Together, this analysis highlights candidate biological
processes that are critical in BRCA1 tumorigenesis beyond the
potential of cell proliferation.
Markers that differentiate ESR1-negative and
ESR1-positive BRCA1 tumours
To identify markers that more strongly differentiate ESR1-based
BRCA1 classes, we compared gene-sets #1 and #2 using a fold-
change threshold X2 in absolute value (FDR o5%). A total of 31
genes met these criteria (Table 1) and, among these, two of the
most differentially expressed, CD133 and MMP7, were selected
for evaluation in an independent series of BRCA1 tumours
(see Materials and Methods). Immunohistochemical and immuno-
fluorescence assays of both proteins strongly correlated with the
gene expression results (Figure 2): MMP7 showed strong staining
in B80% (9 out of 11) of the ER-negative tumours but in none of
the ER-positive tumours (0 out of 4), and CD133 showed strong
staining in 90% of the ER-negative tumours (10 out of 11) but
was completely absent from the four ER-positive tumours
(P-values¼0.011 and 0.004, respectively).
Putative prognostic value of the immune response
The association between gene-set #2 and the immune response was
narrowed down using child GO terms such as Cytokine and
Chemokine Mediated Signalling Pathway or Lymphocyte Prolife-
ration. Overall, 52 genes in gene-set #2 with annotations from these
processes were identified and most were over-expressed in the
ESR1-negative BRCA1 tumours. Next, using gene-set #2, an
unsupervised clustering of these tumours identified two possible
subclasses distinguished by the expression level of several
transcripts in these processes (Figure 3A).
The expression level of immune response genes has recently
been shown to provide prognostic value for sporadic ER-negative
breast tumours (Teschendorff et al, 2007) and this biological
process seems to be commonly present in breast cancer prognosis
signatures (Reyal et al, 2008). Examination of gene-set #2 and the
signature of Teschendorff et al (2007) identified 18 genes in
common, which is higher than the number expected by chance
(P-value o10
 7). In agreement with this observation, differential
expression of several genes in set #2 has also been associated with
breast cancer metastasis, to the bone (CX3CL1, FARSLA, FST,
GBP2, HLADPA1, HLADPB1, HLADRB1, MITF, NEDD4L, SERPI-
NA1 and TGFBI) (Kang et al, 2005) or to the lung (ALDH3A1,
COL1A1, EFEMP1, GSN, HLADPA1, HLADPB1, MAN1A1, PTPRN2
and TNC) (Minn et al, 2005). In both metastatic conditions, the
number of genes in common with gene-set #2 is higher than
randomly expected (P-values o0.05). This suggests the putative
association between gene-set #2 and BRCA1 prognosis. Although
the immune response gene-set is differentially expressed in the
same direction in all ESR1-negative BRCA1 tumours examined
here, it can stratify tumours in at least two additional subclasses
(Figure 3a and b) depending on the magnitude of the expression of
specific genes (Supplementary Table S5). The transcript levels of
genes that overlap with the good prognostic signature of sporadic
ER-negative tumours were higher in class B.
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sExamination of independent series of ER-negative BRCA1
tumours
The observed association with the immune response and with
metastasis genes indicated a possible prognostic value of the
expression profiles of gene-set #2. We then examined the profiles
and their association with histopathological or clinical variables in
an independent series of ER-negative BRCA1 tumours (van‘t Veer
et al, 2002). Unsupervised clustering using genes differentially
expressed in our series of ER-negative tumours with Bonferroni
X05T126
X58
X62
X02T329D
X17
X36
X15
X33
X1
X28
X02T144
X04T91
X02T329I
X3
ESR1-negative ESR1-positive
X15
X1
X36
X17
X05T126
X62
X58
X02T329D
X33
X02T144
X3
X04T91
X02T329I
X28
< −1 0 > +1
Log ratio
CDH3
ELOVL5
SQLE
CHI3L1
KRT7
CCNE1
CRYAB
CX3CL1
DMD
CAPN3
CXCL1
ANXA1
FZD7
KIT
KRT5
VIM
RERG
MAD2L1
KIF23
STAR
PRNPIP
PIK3R1
PPARBP
GGH
LAPTM4B
EGFR
RBP4
FABP3
GPX3
TGFB1
TGFBR2
KRT17
ITGB4
DECR2
FHL2
ACOX2
TNC
TNF
MFGE8
TRIM29
SCUBE2
EMP2
ESR1
GATA3
LRBA
ERBB2
GRB7
TFF1
HMGCL
PGR
TLK1
MYO6
LAMA2
ITGA7
TFRC
Figure 1 (A) Dendrogram resulting of unsupervised hierarchical clustering of the 14 BRCA1 tumours and 5570 genes that remained after data quality
filtering. Two main clusters are observed mediated by ESR1 expression (left branch encompasses tumours over-expressing ESR1 and right branch those with
modest or no detectable levels of ESR1). (B) Unsupervised hierarchical clustering of the 14 BRCA1 tumours using the transcript levels of 55 genes
representing markers of the five distinct subclasses of sporadic breast tumours (Perou et al, 2000). The same clusters as in the previous analysis are observed
except for sample #33.
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scorrection (n¼94) (Supplementary Table S3) classified tumours
highly according to the presence of lymphocytic infiltrate, as
described by van‘t Veer et al, 2002. This observation is consistent
with the differential expression of immune response genes and
highlighted those genes with greater expression differences in
this condition (Figure 4). Tumour subclasses differed considerably
in terms of presence/absence of angioinvasion, which leads us
to speculate that these genes have a function in the prognosis of
ER-negative BRCA1 breast cancer. Overall, the results for the
independent series support the putative biological significance of
the immune response in the molecular and clinical classification of
BRCA1 tumours.
Examination of independent series of ER-positive tumours
The expression levels of transcripts represented in gene-set #1
(ESR1-positive BRCA1 tumours) were examined in an independent
series of 56 sporadic ER-positive breast tumours (van‘t Veer et al,
2002). This analysis identified a group of tumours with good
prognosis, almost all of which were of low grade and metastasis-
free up to 5 years (Supplementary Figure S1). These good
prognosis tumours were mainly characterised by over-expression
of ERBB3 and down-regulation of cell cycle-related genes such as
CCNA2 and CCNB2. Notably, ERBB3 expression has recently been
associated with favorable clinical outcome of invasive ductal
carcinomas (Lee et al, 2007).
Transcriptional regulation of BRCA1 signatures and
association with the type of germline mutation
To investigate the higher-order regulation of BRCA1 signatures we
combined the analysis of predicted transcription factor binding
sites with the examination of differential expression and profiles in
our series. From the analyses of ER functional genomic data shown
above, it was demonstrated that many genes in set #1 were
regulated directly or indirectly by ER. Examination of JASPAR
transcription factor motifs in the promoters of genes in set #2
indicated over-representation of predicted binding sites of C/EBP
and RELA (Bonferroni corrected Fisher’s exact test P-values
o0.05). Two transcription factors of this family present in our
array, NFkB2 and RELB, showed over-expression in ESR1-negative
BRCA1 tumours with fold changes relative to ESR1-positive
tumours ranging from 3.7 to 4.1, respectively (two-tailed t-test
P-values o0.05.
Consistent with these observations, the expression levels of REL/
NFkB transcription factors classified our ESR1-negative BRCA1
tumours in the same way as observed for the complete gene-set #2,
with two main subclasses (a and b) that differed in the magnitude
of expression change of immune response genes (but not in the
direction) (Figure 3B). Importantly, BRCA1 has been identified as
interacting directly with RELA and, thus, activating NFkB target
genes (Benezra et al, 2003). We then examined the association
between expression profiles and BRCA1 mutation types in our
series. All of the ESR1-negative BRCA1 tumours with low
Table 1 Description of the 31 genes that more strongly differentiate ESR1-based BRCA1 subclasses using a fold-change threshold higher or lower than 2
or  2, respectively, and a FDR lower than 5%
Gene name
(HUGO) Description Chromosome
Start
(bp)
End
(bp) Strand
Fold
change
FDR
P-value
C10orf116 Chromosome 10 open reading frame 116 10 88718168 88720646 + 3.77 6.4207E-04
CD133 Prominin 1 4 15578950 15694453    2.70 1.5661E-02
CRABP2 Cellular retinoic acid binding protein 2 1 154936034 154942232   2.12 7.7835E-03
ERBB3 V-erb-b2 erythroblastic leukemia viral
oncogene
homolog 3 (avian)
12 54760159 54783395 + 2.13 1.0152E-05
ESR1 Estrogen receptor 1 6 152168512 152466099 + 4.25 4.4951E-04
F2RL2 Coagulation factor II (thrombin) receptor-like 2 5 75947064 75954996   2.12 8.3191E-03
GATA3 GATA binding protein 3 10 8136673 8157170 + 3.30 1.3560E-03
GPR98 G protein-coupled receptor 98 5 89945799 90495789 + 3.40 6.0975E-03
HIST1H1C Histone cluster 1, H1c 6 26163894 26164678   2.49 1.6326E-03
HSPB8 Heat shock 22kDa protein 8 12 118100978 118116933 + 2.86 4.4951E-04
LAMP3 Lysosomal-associated membrane protein 3 3 184322698 184363317    2.29 9.6204E-03
LDHB Lactate dehydrogenase B 12 21679543 21702043    2.32 6.4207E-04
LMO4 LIM domain only 4 1 87566739 87587021 +  2.42 1.3021E-03
LOC124220 Similar to common salivary protein 1 16 2820174 2822285 + 3.78 4.8845E-04
LOC391271 Hypothetical LOC391271 21 20719132 20720350   2.65 9.3351E-05
MAML2 Mastermind-like 2 (Drosophila) 11 95349407 95355511    2.14 1.0648E-02
MID1 Midline 1 (Opitz/BBB syndrome) 1 145841560 145848017 +  2.07 2.1773E-02
MMP7 Matrix metallopeptidase 7 (matrilysin, uterine) 11 101896450 101906688    2.85 7.1351E-03
PRAME Preferentially expressed antigen in melanoma 22 21220124 21231696    4.30 4.3286E-04
PSAT1 Phosphoserine aminotransferase 1 9 80101879 80134827 +  2.11 3.2517E-03
REEP5 Receptor accessory protein 5 5 112239980 112285930   2.04 6.4207E-04
RP5-860F19.3 Early B-cell factor 4 20 2612040 2688754 + 2.02 8.3191E-03
RTN4RL1 Reticulon 4 receptor-like 1 17 1786540 1787865   2.28 6.4207E-04
SCUBE2 Signal peptide, CUB domain, EGF-like 2 11 8998511 9069731   4.13 3.3991E-05
SLITRK6 SLIT and NTRK-like family, member 6 13 85264923 85271484   3.57 6.4207E-04
STARD10 StAR-related lipid transfer (START) domain
containing 10
11 72143422 72182398   3.16 3.2803E-04
TFF1 Trefoil factor 1 21 42655462 42659713   3.38 1.3021E-03
TMEM16A Transmembrane protein 16A 11 69602056 69713281 + 2.24 6.1384E-03
TNFRSF21 Tumor necrosis factor receptor superfamily,
member 21
6 47307227 47385321    2.07 1.6305E-03
TSPAN13 Tetraspanin 13 7 16785818 16789424 + 2.34 1.1854E-02
UBD Ubiquitin D 6 29667268 29671562    2.27 2.9004E-02
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sexpression of NFkB originated from BRCA1 truncating mutations
that probably led to a complete absence of the protein through the
nonsense-mediated mRNA decay mechanism (NMD) (Supplemen-
tary Table S4) (Perrin-Vidoz et al, 2002). In contrast, three of the
five BRCA1 ESR1-negative tumours, which showed the highest
levels of NFkB2 and RELB expression, harboured missense
mutations that might led to an aberrant but still present BRCA1
protein.
Figure 2 Validation through immunohistochemical (IHC) and immunofluorescense (IF) assays of the expression results obtained for the MMP7 and
CD133 genes. (A and B) BRCA1 ER-negative tumour over-expressing MMP7. (C and D) BRCA1 ER-positive tumour lacking MMP7 expression. (E and F)
BRCA1 ER-negative tumour over-expressing CD133. (G and H) BRCA1 ER-positive tumour lacking CD133 expression.
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levels of 72 NFkB target genes related to apoptosis and the immune
system (http://people.bu.edu/gilmore/NFkB/target/index.html) in
our ER-negative BRCA1 tumours and in the BRCA1-mutated cell
line MDA-MB-436, showing very low levels of the BRCA1
transcript with respect to the BRCA1-mutated cell line HCC1937
(harbouring a mutation that is known not to trigger NMD) and
other control breast cancer cell lines. Two clusters were again
observed according to the expression of target genes, as described
above, and MDA-MB-436 was classified within the cluster of
tumours showing low expression of NFkB targets (Supplementary
Figure S2).
Higher-level study of BRCA1 signatures
To better understand BRCA1 signatures and their role in breast
tumorigenesis, we examined them in the context of the network of
human protein–protein interactions or interactome network. This
analysis revealed that many proteins encoded by these signatures
are included in a giant component with 235 nodes or proteins and
ab
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Figure 3 (A) Unsupervised hierarchical clustering of the nine ESR1-negative BRCA1 tumours using the gene-set #2. Two subgroup/class/clusters, a (left
branch) and b (right branch), are observed, showing differences in the magnitude of expression of genes related to the immune response. (B) Unsupervised
hierarchical clustering of the nine ESR1-negative BRCA1 tumours using transcription factor genes of the REL/NFkB family. The same subgroup/class/clusters
(a and b) as those found using gene-set #2 are observed.
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s532 edges or interactions (Figure 5), which suggests that the gene
products of gene-sets #1 and #2 work in functionally related
pathways or processes.
Functional relationships between proteins can be defined as
direct interactions, complex memberships or relatively close
connections in the interactome network. To determine the exact
relationships between the proteins considered here, interactome
paths were calculated between proteins encoded by gene-sets #1
and #2 and compared with the complete distribution of shortest
paths in the giant component. The shortest paths identified
between signatures were smaller than those in the giant component
(Mann–Whitney U-test P-value o0.001), which supports the
proposed existence of functional and dynamical relationships
between BRCA1 signatures.
To further examine the functional association between the
signatures, we analysed the representation of GO biological
process terms in their interactome network neighbourhoods
(i.e. proteins that interact directly with each signature, but
excluding proteins that belong to any signature). This analysis
confirmed previously observed over-representation of certain
processes in differentially expressed genes: gene-set #1 showed
significant over-representation of neighbours involved in the
Steroid Hormone Receptor Signalling Pathway, the Cell Cycle and
Cell Death, but not in the Immune Response; and gene-set #2
showed significant over-representation of all these processes
except the Steroid Hormone Receptor Signalling Pathway (Table 2).
These observations show the impact of gene expression changes on
protein associations mediating BRCA1 tumorigenesis.
DISCUSSION
In this study, we analysed the expression profiling of a series of 14
BRCA1 tumours, which gave insights into the biological processes
and molecular wiring diagrams that mediate tumorigenesis.
Although the sample size is small, it is worth to note the difficulty
of collecting frozen tumour samples from familial breast cancer cases
genetically characterised. This is probably the cause of the very few
studies published so far regarding the expression profiling of these
tumours, all of them using sample sizes similar to ours (Hedenfalk
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Figure 4 Unsupervised hierarchical clustering obtained with 94 genes differentially expressed in the ESR1-negative tumours, using the Bonferroni
correction, in 18 BRCA1 and two BRCA2 (#99 and #94) tumours from the external series of van ‘t Veer et al (2002). Clustering of tumours according to
the presence or not of lymphocytic infiltrate and angioinvasion is observed. Relevant genes of breast cancer metastasis and those that more strongly
differentiate clusters are shown. Pathological characteristics are annotated as shown in the inset and follow-up times (months) are shown at the bottom.
Expression values are represented as log2 ratios.
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set al, 2001; van‘t Veer et al, 2002). Sixty percent of the tumours
analysed here showed low or no expression of ESR1 or over-
expressed genes typically found in basal-like tumours, whereas
the remaining tumours showed over-expression of ESR1 and a
nonbasal-like phenotype. The results are in agreement with other
series in which the percentage of BRCA1 breast tumours showing a
basal phenotype defined by immunohistochemical markers ranges
from 44% to almost 100% (Diaz et al, 2007).
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Figure 5 Interactome network of proteins encoded by the gene-sets #1 and #2 as shown in the inset.
Table 2 Over-represented GO terms in the direct or one-hop interactors of proteins encoded by the gene-sets #1 and #2
Gene-set #1 Gene-set #2
(n¼198)
a (n¼632)
a
GO term Number of interactors (FDR P-value)
b Number of interactors (FDR P-value)
b
Cell cycle 159 (o10
 9) 267 (o0.001)
Cell death 138 (o10
 9) 261 (o0.001)
Immune response Nonsignificant 191 (o0.001)
Steroid hormone receptor signaling pathway 28 (o10
 10) Nonsignificant
aNumber of gene products in the interactome network.
bTotal number of interactors and corresponding FDR-adjusted P-value for GO term over-representation.
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In addition to the major classification mediated by ESR1 or basal
markers, this study reveals further complexity of BRCA1 tumours.
Over-representation of transcription DNA-dependent and cell
cycle-related genes and transcripts directly or indirectly regulated
by ER was detected in genes differentially expressed in ESR1-
positive BRCA1 tumours. As cell proliferation-related processes
and the ER signalling pathway are known to have an important
function in breast cancer prognosis (Yager and Davidson, 2006),
we analysed the expression levels of gene-set #1 in an external
series of 56 ER-positive sporadic breast tumours (van‘t Veer et al,
2002). Unsupervised analysis identified a subclass of tumours of
which the majority did not show angioinvasion or metastases
(Supplementary Figure S1). This subclass was characterised by
under-expression of cell-cycle or proliferation-associated genes
such as CCNA2 and CCNB2. As stated above, these features could
explain the less aggressive behaviour of these tumours. An
interesting gene over-expressed in gene-set #1 was ERBB3.
Recently, Lee et al (2007) used immunohistochemistry to analyse
378 sporadic invasive ductal carcinomas. They found an associa-
tion between ERBB3 expression and positive hormonal receptors
status, and an inverse correlation with histological grade, which is
consistent with our findings. Thus, ERBB3 could be not only a
predictor of good prognosis within ER-positive sporadic and
familial breast cancer patients but also a putative therapeutic target
for these tumours.
Analysis of genes differentially expressed in ESR1-negative
BRCA1 tumours revealed over-representation of genes involved in
the immune response and cell cycle. Teschendorff et al (2007)
described five tumour subclasses within the ER-negative class that
can be distinguished according to the patterns of four gene
expression clusters associated with cell cycle, immune response,
extracellular matrix and steroid hormone response. These clusters
were related to clinical outcome, and an association was observed
between good prognosis and over-expression of immune response
genes, independently of the presence of lymphocytic infiltrate. In
the same study, the authors analysed 18 BRCA1 tumours from
van‘t Veer et al (2002) and found that they were most similar to the
cell cycle-positive and immune response-positive subclass. In
agreement with these findings, the two most commonly repre-
sented pathways in our ESR1-negative BRCA1 subclass were the
immune response and the cell cycle. In addition, analysis of gene-
set #2 in ESR1-negative tumours revealed two probable subclasses
distinguished by differences in the magnitude of the expression
change of immune response genes that may link to differences in
prognosis. Additional research, however, in larger and indepen-
dent series is needed to further elucidate this relationship.
Using a similar approach as for gene-set #1, we analysed gene-
set #2 in the 18 BRCA1 tumours of van‘t Veer et al (2002), finding
that the signature was able to classify the samples according to the
presence of infiltrate and absence of angioinvasion (Figure 4).
Lymphocytic infiltrate is known to be associated with good
prognosis (Lee et al, 2006), and a recent study by Kreike et al
(2007) focused on triple-negative sporadic breast tumours revealed
that 5-year metastasis-free survival in patients with a moderate or
large amount of lymphocytic infiltrate in their tumours was 88%,
which was higher than for those with minimal or no lymphocytic
infiltrate. In our case it was not possible to determine whether the
signature could predict patient outcome independently of infiltrate
status, due to the almost perfect correlation between the presence
of infiltrate and absence of angioinvasion, but the same results in
an independent series support the biological significance of the
immune response in the classification of ER-negative BRCA1
tumours.
Two of the 31 most differentially expressed genes between
the ESR1-negative and ESR1-positive BRCA1 tumours, CD133 and
MMP7 (Table 1), were evaluated by immunohistochemistry and
immunofluorescence in an independent series of 15 BRCA1
tumours, previously classified as basal or luminal (Figure 2).
There was good agreement between mRNA and protein levels for
both genes (P-value¼0.011 and 0.004 for MMP7 and CD133,
respectively), supporting our results.
Involvement of NFjB in the regulation of BRCA1
signatures
We combined the prediction of transcription factor binding sites
and the examination of differential expression to determine
which transcription factors could be driving the signatures. The
ER-negative BRCA1 profiles may be regulated by the NFkB complex.
Over-expression of two genes from this family, NFkB2 and RELB,
was then observed consistent with motif predictions (Figure 3B).
Nuclear Factor-kB is a ubiquitous transcription factor that co-
ordinates several gene products such as cell adhesion molecules,
chemokines, cytokines, growth factors and regulators of apoptosis
(Chen et al,1 9 9 9 ) .O v e r - e x p r e s s i o no fN F kB subunits NFkB3 and
NFkB1 were found in a high percentage of breast tumours and are
inversely correlated with ER-status (Wang et al, 2007), which is in
agreement with our findings. Activation of the NFkB pathway has
been mainly related to tumour promotion; however, negative effect
on tumour development has also been reported, especially in
epithelial cells that has lead to the idea that NFkB can either promote
or oppose tumour development (Karin, 2006).
In our series the over-expression of genes related to immune
response is one of the intrinsic characteristics of ESR1-negative
BRCA1 tumours. The expression levels of these genes can be
used to stratify them into two different subgroup/class/clusters
(A and B), which were classified according to the expression levels
of REL/NFkB genes, and a high correlation was also observed with
the expression of apoptosis genes regulated by them such as
PYCARD, BCL2A1, CASP4, TRAF1 and TRAF2 and other NFkB
target genes such as those involved in transcription and the
immunological cascade (CCR5, CD48, NFkB2 and RELB).
It has been suggested that BRCA1 acts as a co-activator of NFkB
(Benezra et al, 2003). It is worth noting that all of the ESR1-
negative BRCA1 tumours in group A, which show low expression
of NFkB, harboured truncating mutations in the central portion of
BRCA1 that are thought to trigger the nonsense-mediated mRNA
decay mechanism (Perrin-Vidoz et al, 2002) (Supplementary Table
S4). Interestingly, the BRCA1 cell line MDA-MB-436, which
showed lower levels of the BRCA1 transcript than those found in
control breast cancer cell lines measured by quantitative RT–PCR
(data not shown), had the same pattern of NFkB-related gene
expression as the ESR1-negative-A tumours. In contrast, 60% of
the ESR1-negative tumours (group B), which show the highest
expression of NFkB2 and RELB, harboured missense mutations in
BRCA1, which could produce aberrant proteins but conserving
some activities such as the capacity to activate the NFkB
machinery. Given the limited size of our series, whether these
findings are stable and could be relevant to the prognosis of
BRCA1 mutation carriers depending on the activation of NFkB
target genes should be further analysed in a larger sample set.
CONCLUSIONS
In summary, in this study we have established the gene expression
profiling of a series of BRCA1 tumours and found that there is a
further degree of heterogeneity beyond the main classification by
the expression of ESR1 and the presence or absence of a basal-like
phenotype. We have identified specific signatures for ESR1-
positive and ESR1-negative BRCA1 tumours, the latter charac-
terised by the enrichment of immune response and cell-cycle
genes, and have found that slight differences in the level of
expression of the immune response stratify the ER-negative
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NFkB could be a major driver responsible for the levels of both
immune response and apoptotic genes in this tumour group/class/
cluster.
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